SRU Biosystems Announces Issuance of 20th Patent in the Field of Label-Free Optical Biosensors and Instrumentation
News Nov 08, 2007
SRU Biosystems has announced the issuance of their 20th patent in the field of label-free optical biosensors and instrumentation. The patent, US 7,264,973, includes claims specifically covering the label-free detection of cells on the Company’s optical biosensor.
The patent adds to the expansive coverage that the Company has secured for its core technologies, including its instrumentation, microplate designs, and product applications.
“The issuance of the 20th patent, with an additional 7 patent applications that have been allowed, is part our ongoing strategy for the Company to protect its broad intellectual property in the field of optical biosensors,” said Richard Wagner, President and CEO of SRU Biosystems.
“As part of our portfolio management, we will continue to seek worldwide protection for our innovative inventions in this exciting area.”
The patent is related to the SRU BIND® technology, including instrumentation, such as the BIND® Reader, capable of 96- and 384-well microplate detection.
The SRU BIND® Reader can be integrated into automated systems and represents solutions for antibody and small molecule/fragment screening, and cell-based applications.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE